Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU

Boehringer Ingelheim launches first PCV-2 / PRRS vaccine combination
This combination provides simple protection against two major respiratory pathogens in one shot
It also enhances the flexibility of vaccination protocols in pig production thus contributing to better pig well-being

Ingelheim, Germany, September 15, 2021 – Boehringer Ingelheim, a global leader in animal health, announces positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU®, received in the European Union. The combined administration of both vaccines represents innovation in pig health management. From now on, two of the most prominent and costly diseases, Porcine Circovirus Disease (PCVD) and Porcine Reproductive and Respiratory Syndrome (PRRS), can be prevented with a single injection. In modern pig production most pigs receive vaccines to protect against these two diseases.

It is globally the first and only product of its kind.¹ With this freshly mixed combination of vaccines, vaccination schedules can be better targeted to specific epidemiological disease situations. This innovation can also help enhance and improve animal welfare as well as overall animal husbandry by reducing vaccination stress and animal handling. The freshly mixed use of Ingelvac CircoFLEX® and Ingelvac® PRRS MLV is already registered in the US under the tradename FLEX CircoPRRS®.

“We are very proud that we can now also supply veterinarians and pig producers with the latest innovation: the simultaneous use of Ingelvac CircoFLEX® and our PRRS vaccines. It will help them tremendously in reducing the number of injections to pigs, in supporting well-being of their animals and the farm economics by saving on costly labor,” comments Eva Joras, Global Brand Manager FLEX vaccines at Boehringer Ingelheim Animal Health.

“FLEX CircoPRRS®, together with the FreVAX® needle free smart vaccination device launched this year, is another innovation that improves the lives of the pigs under our care, whilst enhancing the vaccination process for vets and producers,” concludes Dr Markus Hammer, Global Head of Swine, Boehringer Ingelheim Animal Health.

About Ingelvac CircoFLEX®

Ingelvac CircoFLEX® is a PCV-2 vaccine that has protected over 3 Billion pigs, globally. The brand is registered for use as a single vaccination for pigs around weaning for effective control of porcine circovirus disease (PCVD). It is manufactured using the proprietary DiaTEC diafiltration technology, resulting in the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed with PRRS modified live virus vaccines on farm.

About Ingelvac PRRSFLEX EU®

Ingelvac PRRSFLEX® EU is the only piglet specific PRRS vaccine against PRRSV type 1 infection to maximize pig performance in all stages of production. For active immunization of clinically healthy pigs from 17 days of age from farms affected with PRRSV type 1 to reduce clinical respiratory symptoms of PRRS virus infection. The product is administered 1 ml/dose via a single intramuscular injection and can be freshly mixed with Ingelvac CircoFLEX® on farm.

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.